Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

GestVision reports on urine test for preeclampsia

GestVision reports researchers have demonstrated that CRD (Congo Red Dot) urine diagnostic test results strongly correlate with a diagnosis of preeclampsia. “This is an important...

| By Bill Kelly

Biohaven acquires Priority Review Voucher

Biohaven Pharmaceutical Holding Company has purchased an FDA Priority Review Voucher to use with the NDA submission of rimegepant Zydis® ODT in the second quarter of 2019 …...

| By Kelley Gipson

Cybrexa unveils rucaparib as PARP inhibitor

Cybrexa Therapeutics reports that the FDA- and EMA-approved poly ADP-ribose polymerase (PARP) inhibitor rucaparib (marketed as Rubraca®) is conjugated in lead candidate CBX-11 (alphalex™-rucaparib). The...

| By Kelley Gipson

Farmington’s CaroGen lands $1.4M grant re HBV

Farmington-based immunotherapy startup CaroGen reports it has won a $1.4 million grant from the National Institutes of Health to accelerate development of its lead drug candidate, a potential...

| By Kelley Gipson

5/1 deadline for ‘Innovation to Impact’ grants

Innovation to Impact at Yale announces a small grant competition for promising innovators committed to addressing substance abuse and addiction. Innovators will apply for one...

| By Kelley Gipson

Cybrexa to present data re its lead candidate

Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the upcoming...

| By Kelley Gipson

Microsoft features InveniAI in series ‘AI for Change’

InveniAI® Corporation was featured in a Microsoft-sponsored series that showcases companies making a transformative impact in their industry with AI technology. Krishnan Nandabalan, Ph.D., President...

| By Kelley Gipson

Alexion announces two new collaborations

Alexion Pharmaceuticals and Zealand Pharma are collaborating to discover and develop novel peptide therapies for complement-mediated diseases. Peptides offer a number of advantages, including being...

| By Kelley Gipson

UConn TIP fosters business opportunities

Mostafa Analoui, Executive Director of Venture Development at the University of Connecticut, recently spoke to MetroHartford Alliance about what brought him to Connecticut, his role...